Patient characteristics
| Patient . | Sex/age, y . | Diagnosis . | Status at vaccination . | Previous treatment . | Prevaccination PR1+CD8+ T cells, % (absolute PR1+CD8+ T cells/mL) . | Prevaccination WT1+CD8+ T cells, % (absolute WT1+CD8+ T cells/mL) . | Max postvaccination PR1+CD8+ T cells, % (absolute PR1+CD8+ T cells/mL) . | Onset of PR1+CD8+ T cells, wk after V . | Max postvaccination WT1+CD8+ T cells, % (absolute PR1+CD8+ T cells/mL) . | Onset of WT1+CD8+ T cells, wk after V . | Sideeffects (grade) . | Current status (d after V) . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M/42 | MDS | RARS | Epo/G-CSF | 0.04 (70) | 0.06 (105) | 0.04 (111) | 1 | 0.19 (471) | 1 | Local (1) | SD (523) |
| 2 | M/41 | MDS | RA | Epo | 0.00 (0) | 0.16 (423) | 0.34 (878) | 2 | 0.42 (1085) | 2 | Local (1) | SD (446) |
| 3 | M/76 | AML | CR1 | Standard chemo | 0.04 (199) | 0.01 (49) | 0.48 (3981) | 2 | 0.16 (944) | 1 | Local (1) | CR (158) |
| 4 | F/48 | AML | CR2 | MUD (×2) | 0.21 (1580) | 0.03 (301) | 0.42 (3820) | 1 | 0.41 (4570) | 2 | Local (1) | CR (278) |
| 5 | M/71 | Ph+ AML | CR1 | Standard chemo | 0.04 (53) | 0.02 (107) | 0.34 (644) | 1 | 0.02 (113) | Local (1), systemic (2) | Rel (198) | |
| 6 | M/55 | AML | CR1 | Standard chemo | 0.11 (276) | 0.03 (75) | 0.25 (606) | 1 | 0.05 (218) | 1 | Local (1) | Rel (145) |
| 7 | M/54 | CML | CP | Imatinib | 0.04 (144) | 0.03 (86) | 0.11 (279) | 3 | 0.01 (98) | Local (1) | Mol R (164) | |
| 8 | M/55 | AML | CR1 | Standard chemo | 0.00 (0) | 0.01 (20) | 0.36 (264) | 2 | 0.38 (325) | 1 | Local (1) | CR (105) |
| Patient . | Sex/age, y . | Diagnosis . | Status at vaccination . | Previous treatment . | Prevaccination PR1+CD8+ T cells, % (absolute PR1+CD8+ T cells/mL) . | Prevaccination WT1+CD8+ T cells, % (absolute WT1+CD8+ T cells/mL) . | Max postvaccination PR1+CD8+ T cells, % (absolute PR1+CD8+ T cells/mL) . | Onset of PR1+CD8+ T cells, wk after V . | Max postvaccination WT1+CD8+ T cells, % (absolute PR1+CD8+ T cells/mL) . | Onset of WT1+CD8+ T cells, wk after V . | Sideeffects (grade) . | Current status (d after V) . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M/42 | MDS | RARS | Epo/G-CSF | 0.04 (70) | 0.06 (105) | 0.04 (111) | 1 | 0.19 (471) | 1 | Local (1) | SD (523) |
| 2 | M/41 | MDS | RA | Epo | 0.00 (0) | 0.16 (423) | 0.34 (878) | 2 | 0.42 (1085) | 2 | Local (1) | SD (446) |
| 3 | M/76 | AML | CR1 | Standard chemo | 0.04 (199) | 0.01 (49) | 0.48 (3981) | 2 | 0.16 (944) | 1 | Local (1) | CR (158) |
| 4 | F/48 | AML | CR2 | MUD (×2) | 0.21 (1580) | 0.03 (301) | 0.42 (3820) | 1 | 0.41 (4570) | 2 | Local (1) | CR (278) |
| 5 | M/71 | Ph+ AML | CR1 | Standard chemo | 0.04 (53) | 0.02 (107) | 0.34 (644) | 1 | 0.02 (113) | Local (1), systemic (2) | Rel (198) | |
| 6 | M/55 | AML | CR1 | Standard chemo | 0.11 (276) | 0.03 (75) | 0.25 (606) | 1 | 0.05 (218) | 1 | Local (1) | Rel (145) |
| 7 | M/54 | CML | CP | Imatinib | 0.04 (144) | 0.03 (86) | 0.11 (279) | 3 | 0.01 (98) | Local (1) | Mol R (164) | |
| 8 | M/55 | AML | CR1 | Standard chemo | 0.00 (0) | 0.01 (20) | 0.36 (264) | 2 | 0.38 (325) | 1 | Local (1) | CR (105) |
Significant PR1- and WT1-specific CD8+ T-cell responses are highlighted. The percentages of PR1- and WT1-specific CD8+ T cells as a fraction of CD8+ T cells and the absolute numbers of PR1- and WT1-specific CD8+ T cells/mL before and after vaccination are presented for each patient.
V indicates vaccination; Max, maximum; RARS, refractory anemia with ringed sideroblasts; G-CSF, granulocyte colony stimulating factor; SD, stable disease; CR, complete remission; chemo, chemotherapy; MUD, matched unrelated donor transplantation; Ph: Philadelphia; Rel, relapse; CP, chronic phase; and Mol R, molecular response.